Influences of Dopaminergic Treatment on Motor Cortex in Parkinson Disease : A MRI/MRS Study
Identifieur interne : 001460 ( PascalFrancis/Corpus ); précédent : 001459; suivant : 001461Influences of Dopaminergic Treatment on Motor Cortex in Parkinson Disease : A MRI/MRS Study
Auteurs : Claudio Lucetti ; Paulo Del Dotto ; Gianna Gambaccini ; Roberto Ceravolo ; Chiara Logi ; Caterina Berti ; Giuseppe Rossi ; Maria Cristina Bianchi ; Michela Tosetti ; Luigi Murri ; Ubaldo BonuccelliSource :
- Movement disorders [ 0885-3185 ] ; 2007.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
The objective of this study was to investigate neurochemical and metabolic changes in the motor cortex in a group of de novo Parkinson's disease (PD) patients before and after 6 mo treatment with the dopamine agonist pergolide. Proton magnetic resonance spectroscopy (1H-MRS) has been used to study striatal and cortical metabolism in PD and other parkinsonisms. So far, no studies evaluating possible brain metabolic changes in PD patients before and after dopaminergic therapy have been reported. De novo PD patients (11) and controls (11) underwent clinical evaluation (UPDRS-III motor evaluation) and a first single-voxel 1H-MRS of the motor cortex. 1H-MRS studies were performed using the PROBE-SV System implemented on a 1.5 Tesla Scanner (GE Medical System, Milwaukee, WI). Pergolide was administered up to a dose of 1 mg t.i.d. After 6 mo follow-up, all patients were clinically evaluated and a second single-voxel 1H-MRS was performed. Lower values of Cho/Cr and NAA/Cr ratios were observed in the motor cortex of PD patients compared with controls (P < 0.02 and P < 0.01, respectively). After 6 mo therapy with pergolide (1 mg t.i.d), PD patients showed an improvement in motor performances (P < 0.05) and an increase in Cho/Cr ratios in the motor cortex at the second 1H-MRS evaluation (P < 0.05) was reported. In conclusion, cortical NAA/Cr and Cho/Cr ratios may be impaired in de novo PD. Dopaminergic therapy capable of improving motor function may restore the Cho/Cr ratio in the motor cortex.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
|
---|
Format Inist (serveur)
NO : | PASCAL 08-0071401 INIST |
---|---|
ET : | Influences of Dopaminergic Treatment on Motor Cortex in Parkinson Disease : A MRI/MRS Study |
AU : | LUCETTI (Claudio); DEL DOTTO (Paulo); GAMBACCINI (Gianna); CERAVOLO (Roberto); LOGI (Chiara); BERTI (Caterina); ROSSI (Giuseppe); BIANCHI (Maria Cristina); TOSETTI (Michela); MURRI (Luigi); BONUCCELLI (Ubaldo) |
AF : | Department of Neuroscience, University of Pisa/Italie (1 aut., 3 aut., 4 aut., 5 aut., 6 aut., 10 aut., 11 aut.); Neurology Unit, Hospital of Viareggio/Italie (2 aut.); Epidemiology and Biostatistics Unit, Institute of Clinical Physiology -CNR Pisa/Italie (7 aut.); Department of Neuroradiology, Hospital of Pisa/Italie (8 aut.); Laboratory of Magnetic Resonance, IRCCS Stella Maris/Pisa/Italie (8 aut., 9 aut.) |
DT : | Publication en série; Niveau analytique |
SO : | Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2007; Vol. 22; No. 15; Pp. 2170-2175; Bibl. 34 ref. |
LA : | Anglais |
EA : | The objective of this study was to investigate neurochemical and metabolic changes in the motor cortex in a group of de novo Parkinson's disease (PD) patients before and after 6 mo treatment with the dopamine agonist pergolide. Proton magnetic resonance spectroscopy (1H-MRS) has been used to study striatal and cortical metabolism in PD and other parkinsonisms. So far, no studies evaluating possible brain metabolic changes in PD patients before and after dopaminergic therapy have been reported. De novo PD patients (11) and controls (11) underwent clinical evaluation (UPDRS-III motor evaluation) and a first single-voxel 1H-MRS of the motor cortex. 1H-MRS studies were performed using the PROBE-SV System implemented on a 1.5 Tesla Scanner (GE Medical System, Milwaukee, WI). Pergolide was administered up to a dose of 1 mg t.i.d. After 6 mo follow-up, all patients were clinically evaluated and a second single-voxel 1H-MRS was performed. Lower values of Cho/Cr and NAA/Cr ratios were observed in the motor cortex of PD patients compared with controls (P < 0.02 and P < 0.01, respectively). After 6 mo therapy with pergolide (1 mg t.i.d), PD patients showed an improvement in motor performances (P < 0.05) and an increase in Cho/Cr ratios in the motor cortex at the second 1H-MRS evaluation (P < 0.05) was reported. In conclusion, cortical NAA/Cr and Cho/Cr ratios may be impaired in de novo PD. Dopaminergic therapy capable of improving motor function may restore the Cho/Cr ratio in the motor cortex. |
CC : | 002B17; 002B17G; 002B17A03 |
FD : | Pathologie du système nerveux; Maladie de Parkinson; Traitement; Cortex moteur; Imagerie RMN; Stimulant dopaminergique; Pergolide |
FG : | Encéphale; Système nerveux central; Voie motrice; Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central |
ED : | Nervous system diseases; Parkinson disease; Treatment; Motor cortex; Nuclear magnetic resonance imaging; Dopamine agonist; Pergolide |
EG : | Encephalon; Central nervous system; Motor pathway; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease |
SD : | Sistema nervioso patología; Parkinson enfermedad; Tratamiento; Corteza motora; Imaginería RMN; Estimulante dopaminérgico; Pergolida |
LO : | INIST-20953.354000162671070050 |
ID : | 08-0071401 |
Links to Exploration step
Pascal:08-0071401Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Influences of Dopaminergic Treatment on Motor Cortex in Parkinson Disease : A MRI/MRS Study</title>
<author><name sortKey="Lucetti, Claudio" sort="Lucetti, Claudio" uniqKey="Lucetti C" first="Claudio" last="Lucetti">Claudio Lucetti</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neuroscience, University of Pisa</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Del Dotto, Paulo" sort="Del Dotto, Paulo" uniqKey="Del Dotto P" first="Paulo" last="Del Dotto">Paulo Del Dotto</name>
<affiliation><inist:fA14 i1="02"><s1>Neurology Unit, Hospital of Viareggio</s1>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gambaccini, Gianna" sort="Gambaccini, Gianna" uniqKey="Gambaccini G" first="Gianna" last="Gambaccini">Gianna Gambaccini</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neuroscience, University of Pisa</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ceravolo, Roberto" sort="Ceravolo, Roberto" uniqKey="Ceravolo R" first="Roberto" last="Ceravolo">Roberto Ceravolo</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neuroscience, University of Pisa</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Logi, Chiara" sort="Logi, Chiara" uniqKey="Logi C" first="Chiara" last="Logi">Chiara Logi</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neuroscience, University of Pisa</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Berti, Caterina" sort="Berti, Caterina" uniqKey="Berti C" first="Caterina" last="Berti">Caterina Berti</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neuroscience, University of Pisa</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rossi, Giuseppe" sort="Rossi, Giuseppe" uniqKey="Rossi G" first="Giuseppe" last="Rossi">Giuseppe Rossi</name>
<affiliation><inist:fA14 i1="03"><s1>Epidemiology and Biostatistics Unit, Institute of Clinical Physiology -CNR Pisa</s1>
<s3>ITA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bianchi, Maria Cristina" sort="Bianchi, Maria Cristina" uniqKey="Bianchi M" first="Maria Cristina" last="Bianchi">Maria Cristina Bianchi</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neuroradiology, Hospital of Pisa</s1>
<s3>ITA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Laboratory of Magnetic Resonance, IRCCS Stella Maris</s1>
<s2>Pisa</s2>
<s3>ITA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tosetti, Michela" sort="Tosetti, Michela" uniqKey="Tosetti M" first="Michela" last="Tosetti">Michela Tosetti</name>
<affiliation><inist:fA14 i1="05"><s1>Laboratory of Magnetic Resonance, IRCCS Stella Maris</s1>
<s2>Pisa</s2>
<s3>ITA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Murri, Luigi" sort="Murri, Luigi" uniqKey="Murri L" first="Luigi" last="Murri">Luigi Murri</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neuroscience, University of Pisa</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bonuccelli, Ubaldo" sort="Bonuccelli, Ubaldo" uniqKey="Bonuccelli U" first="Ubaldo" last="Bonuccelli">Ubaldo Bonuccelli</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neuroscience, University of Pisa</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0071401</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 08-0071401 INIST</idno>
<idno type="RBID">Pascal:08-0071401</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001460</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Influences of Dopaminergic Treatment on Motor Cortex in Parkinson Disease : A MRI/MRS Study</title>
<author><name sortKey="Lucetti, Claudio" sort="Lucetti, Claudio" uniqKey="Lucetti C" first="Claudio" last="Lucetti">Claudio Lucetti</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neuroscience, University of Pisa</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Del Dotto, Paulo" sort="Del Dotto, Paulo" uniqKey="Del Dotto P" first="Paulo" last="Del Dotto">Paulo Del Dotto</name>
<affiliation><inist:fA14 i1="02"><s1>Neurology Unit, Hospital of Viareggio</s1>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gambaccini, Gianna" sort="Gambaccini, Gianna" uniqKey="Gambaccini G" first="Gianna" last="Gambaccini">Gianna Gambaccini</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neuroscience, University of Pisa</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ceravolo, Roberto" sort="Ceravolo, Roberto" uniqKey="Ceravolo R" first="Roberto" last="Ceravolo">Roberto Ceravolo</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neuroscience, University of Pisa</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Logi, Chiara" sort="Logi, Chiara" uniqKey="Logi C" first="Chiara" last="Logi">Chiara Logi</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neuroscience, University of Pisa</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Berti, Caterina" sort="Berti, Caterina" uniqKey="Berti C" first="Caterina" last="Berti">Caterina Berti</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neuroscience, University of Pisa</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rossi, Giuseppe" sort="Rossi, Giuseppe" uniqKey="Rossi G" first="Giuseppe" last="Rossi">Giuseppe Rossi</name>
<affiliation><inist:fA14 i1="03"><s1>Epidemiology and Biostatistics Unit, Institute of Clinical Physiology -CNR Pisa</s1>
<s3>ITA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bianchi, Maria Cristina" sort="Bianchi, Maria Cristina" uniqKey="Bianchi M" first="Maria Cristina" last="Bianchi">Maria Cristina Bianchi</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neuroradiology, Hospital of Pisa</s1>
<s3>ITA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Laboratory of Magnetic Resonance, IRCCS Stella Maris</s1>
<s2>Pisa</s2>
<s3>ITA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tosetti, Michela" sort="Tosetti, Michela" uniqKey="Tosetti M" first="Michela" last="Tosetti">Michela Tosetti</name>
<affiliation><inist:fA14 i1="05"><s1>Laboratory of Magnetic Resonance, IRCCS Stella Maris</s1>
<s2>Pisa</s2>
<s3>ITA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Murri, Luigi" sort="Murri, Luigi" uniqKey="Murri L" first="Luigi" last="Murri">Luigi Murri</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neuroscience, University of Pisa</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bonuccelli, Ubaldo" sort="Bonuccelli, Ubaldo" uniqKey="Bonuccelli U" first="Ubaldo" last="Bonuccelli">Ubaldo Bonuccelli</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neuroscience, University of Pisa</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dopamine agonist</term>
<term>Motor cortex</term>
<term>Nervous system diseases</term>
<term>Nuclear magnetic resonance imaging</term>
<term>Parkinson disease</term>
<term>Pergolide</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Pathologie du système nerveux</term>
<term>Maladie de Parkinson</term>
<term>Traitement</term>
<term>Cortex moteur</term>
<term>Imagerie RMN</term>
<term>Stimulant dopaminergique</term>
<term>Pergolide</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The objective of this study was to investigate neurochemical and metabolic changes in the motor cortex in a group of de novo Parkinson's disease (PD) patients before and after 6 mo treatment with the dopamine agonist pergolide. Proton magnetic resonance spectroscopy (1H-MRS) has been used to study striatal and cortical metabolism in PD and other parkinsonisms. So far, no studies evaluating possible brain metabolic changes in PD patients before and after dopaminergic therapy have been reported. De novo PD patients (11) and controls (11) underwent clinical evaluation (UPDRS-III motor evaluation) and a first single-voxel 1H-MRS of the motor cortex. 1H-MRS studies were performed using the PROBE-SV System implemented on a 1.5 Tesla Scanner (GE Medical System, Milwaukee, WI). Pergolide was administered up to a dose of 1 mg t.i.d. After 6 mo follow-up, all patients were clinically evaluated and a second single-voxel 1H-MRS was performed. Lower values of Cho/Cr and NAA/Cr ratios were observed in the motor cortex of PD patients compared with controls (P < 0.02 and P < 0.01, respectively). After 6 mo therapy with pergolide (1 mg t.i.d), PD patients showed an improvement in motor performances (P < 0.05) and an increase in Cho/Cr ratios in the motor cortex at the second 1H-MRS evaluation (P < 0.05) was reported. In conclusion, cortical NAA/Cr and Cho/Cr ratios may be impaired in de novo PD. Dopaminergic therapy capable of improving motor function may restore the Cho/Cr ratio in the motor cortex.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>22</s2>
</fA05>
<fA06><s2>15</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Influences of Dopaminergic Treatment on Motor Cortex in Parkinson Disease : A MRI/MRS Study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>LUCETTI (Claudio)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>DEL DOTTO (Paulo)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>GAMBACCINI (Gianna)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>CERAVOLO (Roberto)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>LOGI (Chiara)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>BERTI (Caterina)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>ROSSI (Giuseppe)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>BIANCHI (Maria Cristina)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>TOSETTI (Michela)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>MURRI (Luigi)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>BONUCCELLI (Ubaldo)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neuroscience, University of Pisa</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Neurology Unit, Hospital of Viareggio</s1>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Epidemiology and Biostatistics Unit, Institute of Clinical Physiology -CNR Pisa</s1>
<s3>ITA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Neuroradiology, Hospital of Pisa</s1>
<s3>ITA</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Laboratory of Magnetic Resonance, IRCCS Stella Maris</s1>
<s2>Pisa</s2>
<s3>ITA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA20><s1>2170-2175</s1>
</fA20>
<fA21><s1>2007</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000162671070050</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>34 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0071401</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The objective of this study was to investigate neurochemical and metabolic changes in the motor cortex in a group of de novo Parkinson's disease (PD) patients before and after 6 mo treatment with the dopamine agonist pergolide. Proton magnetic resonance spectroscopy (1H-MRS) has been used to study striatal and cortical metabolism in PD and other parkinsonisms. So far, no studies evaluating possible brain metabolic changes in PD patients before and after dopaminergic therapy have been reported. De novo PD patients (11) and controls (11) underwent clinical evaluation (UPDRS-III motor evaluation) and a first single-voxel 1H-MRS of the motor cortex. 1H-MRS studies were performed using the PROBE-SV System implemented on a 1.5 Tesla Scanner (GE Medical System, Milwaukee, WI). Pergolide was administered up to a dose of 1 mg t.i.d. After 6 mo follow-up, all patients were clinically evaluated and a second single-voxel 1H-MRS was performed. Lower values of Cho/Cr and NAA/Cr ratios were observed in the motor cortex of PD patients compared with controls (P < 0.02 and P < 0.01, respectively). After 6 mo therapy with pergolide (1 mg t.i.d), PD patients showed an improvement in motor performances (P < 0.05) and an increase in Cho/Cr ratios in the motor cortex at the second 1H-MRS evaluation (P < 0.05) was reported. In conclusion, cortical NAA/Cr and Cho/Cr ratios may be impaired in de novo PD. Dopaminergic therapy capable of improving motor function may restore the Cho/Cr ratio in the motor cortex.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17A03</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Traitement</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Treatment</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Cortex moteur</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Motor cortex</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Corteza motora</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Imagerie RMN</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Nuclear magnetic resonance imaging</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Imaginería RMN</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Dopamine agonist</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Pergolide</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Pergolide</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Pergolida</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Encephalon</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervioso central</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Voie motrice</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Motor pathway</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Vía motora</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Pathologie du système nerveux central</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>43</s5>
</fC07>
<fN21><s1>035</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 08-0071401 INIST</NO>
<ET>Influences of Dopaminergic Treatment on Motor Cortex in Parkinson Disease : A MRI/MRS Study</ET>
<AU>LUCETTI (Claudio); DEL DOTTO (Paulo); GAMBACCINI (Gianna); CERAVOLO (Roberto); LOGI (Chiara); BERTI (Caterina); ROSSI (Giuseppe); BIANCHI (Maria Cristina); TOSETTI (Michela); MURRI (Luigi); BONUCCELLI (Ubaldo)</AU>
<AF>Department of Neuroscience, University of Pisa/Italie (1 aut., 3 aut., 4 aut., 5 aut., 6 aut., 10 aut., 11 aut.); Neurology Unit, Hospital of Viareggio/Italie (2 aut.); Epidemiology and Biostatistics Unit, Institute of Clinical Physiology -CNR Pisa/Italie (7 aut.); Department of Neuroradiology, Hospital of Pisa/Italie (8 aut.); Laboratory of Magnetic Resonance, IRCCS Stella Maris/Pisa/Italie (8 aut., 9 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2007; Vol. 22; No. 15; Pp. 2170-2175; Bibl. 34 ref.</SO>
<LA>Anglais</LA>
<EA>The objective of this study was to investigate neurochemical and metabolic changes in the motor cortex in a group of de novo Parkinson's disease (PD) patients before and after 6 mo treatment with the dopamine agonist pergolide. Proton magnetic resonance spectroscopy (1H-MRS) has been used to study striatal and cortical metabolism in PD and other parkinsonisms. So far, no studies evaluating possible brain metabolic changes in PD patients before and after dopaminergic therapy have been reported. De novo PD patients (11) and controls (11) underwent clinical evaluation (UPDRS-III motor evaluation) and a first single-voxel 1H-MRS of the motor cortex. 1H-MRS studies were performed using the PROBE-SV System implemented on a 1.5 Tesla Scanner (GE Medical System, Milwaukee, WI). Pergolide was administered up to a dose of 1 mg t.i.d. After 6 mo follow-up, all patients were clinically evaluated and a second single-voxel 1H-MRS was performed. Lower values of Cho/Cr and NAA/Cr ratios were observed in the motor cortex of PD patients compared with controls (P < 0.02 and P < 0.01, respectively). After 6 mo therapy with pergolide (1 mg t.i.d), PD patients showed an improvement in motor performances (P < 0.05) and an increase in Cho/Cr ratios in the motor cortex at the second 1H-MRS evaluation (P < 0.05) was reported. In conclusion, cortical NAA/Cr and Cho/Cr ratios may be impaired in de novo PD. Dopaminergic therapy capable of improving motor function may restore the Cho/Cr ratio in the motor cortex.</EA>
<CC>002B17; 002B17G; 002B17A03</CC>
<FD>Pathologie du système nerveux; Maladie de Parkinson; Traitement; Cortex moteur; Imagerie RMN; Stimulant dopaminergique; Pergolide</FD>
<FG>Encéphale; Système nerveux central; Voie motrice; Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central</FG>
<ED>Nervous system diseases; Parkinson disease; Treatment; Motor cortex; Nuclear magnetic resonance imaging; Dopamine agonist; Pergolide</ED>
<EG>Encephalon; Central nervous system; Motor pathway; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Sistema nervioso patología; Parkinson enfermedad; Tratamiento; Corteza motora; Imaginería RMN; Estimulante dopaminérgico; Pergolida</SD>
<LO>INIST-20953.354000162671070050</LO>
<ID>08-0071401</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001460 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001460 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PascalFrancis |étape= Corpus |type= RBID |clé= Pascal:08-0071401 |texte= Influences of Dopaminergic Treatment on Motor Cortex in Parkinson Disease : A MRI/MRS Study }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |